EU Updates Health Technology Assessment Procedures
New guidance introduces an observer role and a 15-working-day response window for medical technology and drug consultations.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Does allowing observers at scientific health consultations improve public trust in the approval process?
The Member State Coordination Group on Health Technology Assessment has adopted new procedural guidance for evaluating medicines and medical devices in the European Union. These documents introduce a non-participating observer role for subgroup representatives during scientific consultations.
Why it matters
This update formalizes oversight for health technology assessments, aiming to increase transparency within the consultation process. It impacts how medicines, medical devices, and in vitro diagnostics move through the EU regulatory pipeline.
The standardized consultation procedure now spans 4.5 months, with regulators mandated to provide responses within 15 working days following the submission window. The framework utilizes 12 specialized expert panels, including 10 dedicated to specific medical specialties, to support assessments.
The players
Member State Coordination Group on Health Technology Assessment
An EU regulatory body responsible for coordinating the assessment of medicines, medical devices, and diagnostic tests across member states.
European Commission
The executive branch of the European Union responsible for overseeing regulatory policy and public health announcements.
European Medicines Agency
An EU agency that provides scientific advice and evaluative support for medicines and health technologies.
The details
The updated guidance formalizes a watcher role, allowing designated subgroup representatives to attend meetings between the primary assessor and co-assessor. While these observers may attend, they are explicitly barred from active participation in the discussions. The process may incorporate expertise from the European Medicines Agency or specialized panels to evaluate the technical merits of medicines, medical devices, and in vitro diagnostic tests.
Timeline
22 October 2026: The Member State Coordination Group on Health Technology Assessment adopted the updated procedural guidance.
26 October 2026: The European Commission announced the official publication of the documents.
The Tech Race
These guidelines clarify how regulators integrate technical input into the broader EU joint clinical assessment framework. This shift moves the regulatory process toward a more transparent, standardized model compared to previous fragmented evaluation procedures.
Stakeholders and developers of medical devices and medicines can now apply for the watcher role at the start of their consultation processes. The new 15-working-day response deadline provides a more predictable timeline for firms awaiting regulatory feedback.
The takeaway
The adoption of these rules creates a more structured approach to multi-stakeholder participation in European health technology reviews. Readers should watch for how the first consultations involving the new observer role influence the speed and transparency of final regulatory decisions.
Further reading
For broader trends in regulatory shifts for new therapies, visit our Biotech section.
More information
Review the full procedural guidance documents published by the European Commission.
Live Poll
Does allowing observers at scientific health consultations improve public trust in the approval process?
